Patents Examined by Karen Cheng
  • Pyridazine derivatives as RORc modulators
    Patent number: 10487068
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, A, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: November 26, 2019
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward
  • Protein kinase inhibitors
    Patent number: 10479786
    Abstract: The present invention concerns novel deuterated and non-deuterated cyclic chemical compounds and their corresponding salts thereof active on protein kinases in general, and in particular as inhibitors of protein kinases. Additionally, methods of treating mammals with protein kinase-mediated diseases or conditions by administering a therapeutically effective amount of the novel deuterated or non-deuterated cyclic chemical compound and their corresponding salts thereof.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: November 19, 2019
    Assignee: Princeton Drug Discovery, Inc
    Inventor: Kan He
  • Fused tricyclic imidazo pyrazines as modulators of TNF activity
    Patent number: 10472362
    Abstract: A series of substituted fused tricyclic imidazo pyrazine derivatives and analoges thereof, represented by formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: November 12, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Jag Paul Heer, Uwe Heinelt
  • (R)-N-(adamantyl-2-yl)pyrrolidine-2-carboxamide derivatives for cosmetic use
    Patent number: 10470991
    Abstract: The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: November 12, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Stephanie Boudon, Marc Heidl, Eileen Jackson
  • Hexahydropyrazinotriazinone derivatives as kinase inhibitors
    Patent number: 10450320
    Abstract: A series of 1,2,6,7,9,9a-hexahydropyrazino[1,2-d][1,2,4]triazin-4-one derivatives, substituted in the 8-position by an optionally substituted fused bicyclic heteroaromatic group, and in the 3-position by a range of functional groups, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 22, 2019
    Assignees: UCB Biopharma SPRL, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Helen Tracey Horsley, Richard John Mears, Judi Charlotte Neuss, James Thomas Reuberson
  • Pteridine derivatives as modulators of ROR gamma
    Patent number: 10450314
    Abstract: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: October 22, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steven Richard Brunette, Johanna Csengery, Robert Owen Hughes, Xiang Li, Robert Sibley, Michael Robert Turner, Zhaoming Xiong
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 10441581
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: October 15, 2019
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Compound and organic light-emitting device including the same
    Patent number: 10439149
    Abstract: A compound represented by Formula 1 is provided: wherein Formula 1 is the same as described in the detailed description of the present disclosure. The compound of Formula 1 may be included in a hole transport layer and/or an emission layer of an organic light-emitting device (OLED).
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: October 8, 2019
    Assignee: Samsung Display Co., Ltd.
    Inventors: Haejin Kim, Soobyung Ko, Mieun Jun, Youngkook Kim, Seokhwan Hwang
  • Antifungal compound process
    Patent number: 10428025
    Abstract: The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: October 1, 2019
    Assignees: Mycovia Pharmaceuticals, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: William J. Hoekstra, Christopher M. Yates, Mark Behnke, Asaf Alimardanov, Scott A. David, Douglas Franklin Fry
  • 2-oxindole compounds
    Patent number: 10421748
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: September 24, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • Octahydrocyclopentapyrroles, their preparation and use
    Patent number: 10421720
    Abstract: The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: September 24, 2019
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
  • 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 10414755
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 17, 2019
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Aleem Fazal, Ritesh Bhanudasji Tichkule, Michael Scott Visser
  • Compounds as inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma
    Patent number: 10414739
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The compounds of formula (I) are inhibitors of the YAP/TAZ-TEAD interaction.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 17, 2019
    Assignee: INVENTIVA
    Inventors: Martine Barth, Sylvie Contal, Christian Montalbetti, Luc Spitzer
  • Phenylthiazoles and uses thereof
    Patent number: 10414759
    Abstract: Series of 2-phenyl-4-methylthiazole analogs are disclosed as potential therapeutic agents for the treatment of bacterial infections, especially methicillin-resistant Straphylococcus aureus (MRSA) related infections. A method for the treatment of MRSA-related infections is also claimed.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 17, 2019
    Assignee: Purdue Research Foundation
    Inventors: Mark S. Cushman, Abdelrahman S. Mayhoub, Mohamed Seleem
  • Spiro-isoquinoline-1,4?-piperidine compounds having multimodal activity against pain
    Patent number: 10407428
    Abstract: The present invention relates to spiro-isoquinoline-1,4?-piperidine compounds having dual pharmacological activity towards both the sigma (?) receptor and the ?-opiod receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: September 10, 2019
    Assignee: ESTEVE PHARMACEUTICALS, S.A.
    Inventors: Carmen Almansa-Rosales, Monica Garcia Lopez, Ana-Maria Caamano-Moure
  • Stereochemically defined polypropionates and methods for making and using the same
    Patent number: 10407439
    Abstract: The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: September 10, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. Fang, Hyeong-Wook Choi, Silvio Campagna, Steven Mathieu
  • Antifungal compound process
    Patent number: 10407392
    Abstract: The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: September 10, 2019
    Assignees: Mycovia Pharmaceuticals, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: William J. Hoekstra, Christopher M. Yates, Mark Behnke, Asaf Alimardanov, Scott A. David, Douglas Franklin Fry
  • C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
    Patent number: 10398711
    Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: September 3, 2019
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick
  • Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
    Patent number: 10399989
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 3, 2019
    Assignee: Loxo Oncology, Inc.
    Inventor: Nicolas Guisot
  • Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
    Patent number: 10399990
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 3, 2019
    Assignee: Loxo Oncology, Inc.
    Inventor: Nicolas Guisot